Yes, "zoster vaccine" and "shingles vaccine" are the same thing—both terms refer to vaccines that prevent herpes zoster (shingles).
"Zoster" is simply the medical term for "shingles," so zoster vaccination and shingles vaccination are identical concepts. However, there are two distinct vaccine products available, each with different characteristics 1, 2.
The Two Available Vaccines
Zostavax (ZVL - Zoster Vaccine Live)
- Live attenuated varicella-zoster virus vaccine
- Single-dose administration
- Approved for adults aged 50-79 years
- Contraindicated in immunocompromised individuals due to risk from the live virus 2
- Lower efficacy: 51.3% for HZ prevention, 66.5% for postherpetic neuralgia (PHN) in those ≥60 years 2
- Efficacy wanes significantly over time (from 51.3% to 21.2% at 7-11 years) 2
Shingrix (RZV - Recombinant Zoster Vaccine)
- Recombinant subunit vaccine (non-live)
- Contains VZV glycoprotein E antigen with AS01B adjuvant 3
- Two-dose series given 2-6 months apart 1
- Approved for adults ≥50 years AND immunocompromised adults ≥18 years 3
- Superior efficacy: 97.2% for HZ prevention, 91.3% for those ≥70 years 2
- Sustained protection: >83% efficacy maintained for 8 years, 73% at 10 years 2
Current Recommendations
Shingrix (RZV) is strongly preferred over Zostavax for all eligible adults 1, 2. The 2020 U.S. guidelines and 2024 Taiwan guidelines both recommend RZV as the preferred vaccine due to its:
- Markedly higher efficacy across all age groups
- Longer duration of protection
- Safety in immunocompromised patients (where ZVL is contraindicated)
Key Clinical Points:
- For immunocompetent adults ≥50 years: RZV is preferred; give 2-dose series 2-6 months apart 1
- For immunocompromised adults: Only RZV should be used; ZVL is absolutely contraindicated 1, 2
- Previous Zostavax recipients: Can and should receive RZV at least 2 months after ZVL 1
- Previous herpes zoster infection: Still vaccinate with RZV 1
Common Pitfall:
RZV causes more injection-site reactions (9.5% grade 3) and systemic symptoms (11.4% grade 3) compared to placebo, but these are transient and do not increase serious adverse events 2. Counsel patients about expected reactogenicity to prevent vaccine hesitancy, but emphasize these reactions do not compromise safety.